Abstract: An agent for intra-airway administration comprising a compound having a PDE-IV inhibitory activity or the pharmaceutically acceptable salt thereof as an active ingredient which shows its concentration in lung tissues 350-times or more higher than its concentration in plasma when administered into the airway is provided. An agent for intra-airway administration, wherein the compound having a PDE-IV inhibitory activity is, for example, a benzofuran derivative or a 1,3-benzodioxole derivative is provided.

Abstract: The present invention provides a pharmaceutical composition, which comprises 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1?-cyclopentane] or a pharmaceutically acceptable salt thereof and a steroid agent; an agent for treating and/or preventing a pulmonary disease; the agent which comprises 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1?-cyclopentane] or a pharmaceutically acceptable salt thereof and a steroid agent which are simultaneously or separately with an interval and the like.

Abstract: The present invention provides a therapeutic and/or preventive agent for chronic skin diseases which comprises 7-[2-(3,5-dichloro-4-pyridyl)-1-oxoethyl]-4-methoxy-spiro[1,3-benzodioxol-2,1?-cyclopentane] or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: An inverter power supply system includes a half-bridge inverter circuit which includes a first switching element, a second switching element, a first auxiliary capacitor and a second auxiliary capacitor for converting a DC voltage from a DC power supply circuit to an AC voltage. An output control circuit outputs a first output control signal and a second output control signal with a phase difference of a half cycle to control the inverter circuit. An inverter driving circuit turns on the first (or second) switching element when the first (or second) output control signal turns ON while turning off the first (or second) switching element upon lapse of a first (or second) delay time for allowing the first (or second) auxiliary capacitor to discharge to a predetermined level after the first (or second) output control signal turns OFF.

Abstract: An inverter power supply system includes a half-bridge inverter circuit which includes a first switching element, a second switching element, a first auxiliary capacitor and a second auxiliary capacitor for converting a DC voltage from a DC power supply circuit to an AC voltage. An output control circuit outputs a first output control signal and a second output control signal with a phase difference of a half cycle to control the inverter circuit. An inverter driving circuit turns on the first (or second) switching element when the first (or second) output control signal turns ON while turning off the first (or second) switching element upon lapse of a first (or second) delay time for allowing the first (or second) auxiliary capacitor to discharge to a predetermined level after the first (or second) output control signal turns OFF.

Abstract: The object of the present invention is to provide antiinflammatory agents for airway, foods and drinks, animal feeds, food additives, feed additives and a method for preventing or treating airway inflammations. The object is achieved by providing antiinflammatory agents for airway, foods and drinks, animal feeds, food additives and feed additives, each comprising, as the active ingredient thereof, orotic acid or its derivative or a salt thereof; and a method for preventing or treating airway inflammations which comprises administering orotic acid or its derivative or a salt thereof.

Abstract: An oxygen-containing heterocyclic compound represented by following Formula (I): wherein R1 and R2 independently represent hydrogen, lower alkyl, cyano, —(CH2)n—E1—CO—G1 (wherein E1 represents a bond, O, or NH; and G1 represents hydrogen, substituted or unsubstituted lower alkyl, OR6, or NR7R8; and n represents an integer of 0 to 4), or the like; R1 and R2 are combined to represent a saturated carbon ring together with a carbon atom adjacent thereto; or R2, and R11 or R13 described below are combined to form a single bond; R3 represents hydrogen, phenyl, or halogen; R4 represents hydroxy, lower alkoxy, or the like; A represents —C(R9)(R10)— or O; B represents O, NR11, —C(R12)(R13)—, or —C(R14)(R15)— C(R16)(R17)—; D represents (i) —C(R18)(R19)—X— (wherein X represents —C(R21)(R22)—, S, or NR23), (ii) —C(R19a)═Y— [Y represents —C(R24)—Z— (wherein Z represents

Abstract: A power supply for performing arc-machining operation includes a primary rectifier connected to the commercial AC power source and an inverter coupled to the rectifier. A switching device is provided between the rectifier and the inverter. By controlling the power supplied from the rectifier to the inverter, the switching device prevents a large switching loss from occurring in the inverter.

Abstract: A power supply for performing arc-machining operation includes a primary rectifier connected to the commercial AC power source and an inverter coupled to the rectifier. A switching device is provided between the rectifier and the inverter. By controlling the power supplied from the rectifier to the inverter, the switching device prevents a large switching loss from occurring in the inverter.

Abstract: The present invention relates to oxygen-containing heterocyclic compounds represented by the following formula (I): 1

Abstract: An oxygen-containing heterocyclic compound represented by following Formula (I): wherein R1 and R2 independently represent hydrogen, lower alkyl, cyano, —(CH2)n—E1—CO—G1 (wherein E1 represents a bond, O, or NH; and G1 represents hydrogen, substituted or unsubstituted lower alkyl, OR6, or NR7R8; and n represents an integer of 0 to 4), or the like; R1 and R2 are combined to represent a saturated carbon ring together with a carbon atom adjacent thereto; or R2, and R11 or R13 described below are combined to form a single bond; R3 represents hydrogen, phenyl, or halogen; R4 represents hydroxy, lower alkoxy, or the like; A represents —C(R9)(R10)— or O; B represents O, NR11, —C(R12)(R13)—, or —C(R14)(R15)—C(R16)(R17)—; D represents (i) —C(R18)(R19)—X— (wherein X represents —C(R21)(R22)—, S, or NR23), (ii) —C(R19a)═Y— [Y represents —C(R24)—Z— (wherein Z represents C

Abstract: An oxygen-containing heterocyclic compound represented by following Formula (I): 1

Abstract: The present invention relates to benzofuran derivatives represented by following general formula (I): wherein R1 represents lower alkyl, R2 represents hydrogen or substituted or unsubstituted lower alkyl, R3, R4, R5 and R6 independently represent hydrogen or lower alkyl, X represents CH2 or C═O, and Y represents CH2 or NH, or pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to oxygen-containing heterocyclic compounds represented by the following formula (I): wherein m represents an integer of 0 to 4; R1, R2, R3 and R4 independently represent a hydrogen atom, substituted or unsubstituted lower alkyl, etc.; R5 represents substituted or unsubstituted lower alkoxy etc.; R6 represents a hydrogen atom etc.; and Y represents the following formula (II): wherein R9 represents cyano etc., R10 represents a hydrogen atom etc., R11 represents carboxy etc., and R12 represents a hydrogen atom etc.; and the like; or pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to oxygen-containing heterocyclic compounds represented by the following formula (I): 1

Abstract: The present invention relates to novel imidazonaphthyridine derivatives represented by the following formulae: ##STR1## wherein R represents hydrogen, lower alkyl or --CH.sup.2 R.sup.1 (where R.sup.1 represents phenyl or pyridyl) and pharmaceutically acceptable salts thereof.The compounds exhibit excellent anti-allergic, anti-inflammatory and anti-asthmatic activities.

Abstract: The present invention relates to a thienoimidazopyridone derivative represented by Formula (I): ##STR1## wherein A and B independently represent --S-- or --CH.dbd., X-Y-Z represents --N(R.sup.2)--CH.dbd.N-- or --N.dbd.CH--N (R.sup.2)-- wherein R.sup.2 is hydrogen, lower alkyl or --CH(R.sup.3)--(CH.sub.2).sub.n --R.sup.4 wherein R.sup.4 is phenyl, n is 0 or 1, and R.sup.3 is hydrogen or lower alkyl, and R.sup.1 represents lower alkyl, or a pharmaceutically acceptable salt thereof.

Abstract: There are disclosed s-triazolo[3,4-i]purine derivatives represented by formula: ##STR1## wherein Y-Z represents ##STR2## R.sub.4 represents hydrogen, alkyl, substituted or unsubstituted aromatic heterocyclic group or substituted or unsubstituted aryl; and X.sup.2 represents oxygen, sulfur or NH; each of R.sup.1 and R.sup.2 independently represents hydrogen, alkyl, cycloalkyl, aralkyl or substituted or unsubstituted aryl; R.sup.3 represents alkyl, cycloalkyl, aralkyl or substituted or unsubstituted aryl; X.sup.1 represents oxygen or sulfur; and represents a single bond or a double bond or pharmaceutically acceptable salts thereof.

Abstract: Disclosed is a novel arylalkylamine derivative represented by the formula (I) ##STR1## wherein X represents --O--, --CH.sub.2 -- or --NR.sup.3 -- in which R.sup.3 represents hydrogen or lower alkyl;Y represents --NH-- or ##STR2## Z represents ##STR3## in which R.sup.4 represents hydrogen or lower alkyl or ##STR4## Q represents an optionally substituted aryl or optionally substituted aromatic heterocyclic group; each of R.sup.1 and R.sup.2 independently represents hydrogen or lower alkyl;each of m and n independently represents an integer of 0 or 1; anda pharmaceutically acceptable salt thereof. The compound (I) and a pharmaceutically acceptable salt thereof show bronchodilatory and antiallergic activities, and are useful for treating respiratory disorders such as bronchial asthma.

Abstract: Novel dibenz[b,e]oxepin derivatives are employed in the treatment and control of allergic conditions such as allergic asthma and also employed in the treatment of inflammation.